ghrelin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical use for the treatment of sexual dysfunction but are not yet approved. Sexual function disorders include anorgasmia, atrophic vaginitis (vaginal atrophy), decreased libido, dyspareunia (painful sexual intercourse), erectile dysfunction, female sexual dysfunction (female sexual arousal disorder (FSAD)/hypoactive sexual desire disorder (HSSD)), male sexual dysfunction, premature ejaculation, vulvodynia (vulva pain), paraphilias, and hypersexuality, among others. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in January 2026. It is likely to become outdated with time.
In the first reaction, the two substrates are 3-phosphoglyceric acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are phosphohydroxypyruvic acid (i.e. 3-phosphonooxypyruvic acid), reduced NADH, and a proton. This enzyme can also catalyse the interconversion of α-hydroxyglutaric acid and α-ketoglutaric acid using the same cofactors.
=== Automobile systems === Urea is used in Selective Non-Catalytic Reduction (SNCR) and Selective Catalytic Reduction (SCR) reactions to reduce the NOx pollutants in exhaust gases from diesel, dual fuel, and lean-burn natural gas engines. The BlueTec system, for example, injects a water-based urea solution into the exhaust system. Ammonia (NH3) produced by the hydrolysis of urea reacts with nitrogen oxides (NOx) and is converted into nitrogen gas (N2) and water within the catalytic converter. The conversion of noxious NOx to innocuous N2 is described by the following simplified global equation:
Sources: en.wikipedia.org
The thrifty gene hypothesis (also called the famine hypothesis) states that in some populations the body would be more efficient at retaining fat in times of plenty, thereby endowing greater resistance to starvation in times of food scarcity. This hypothesis, originally advanced in the context of glucose metabolism and insulin resistance, has been discredited by physical anthropologists, physiologists, and the original proponent of the idea himself with respect to that context, although according to its developer it remains "as viable as when [it was] first advanced" in other contexts. In 1995, Jeffrey Friedman, in his residency at the Rockefeller University, together with Rudolph Leibel, Douglas Coleman et al. discovered the protein leptin that the genetically obese mouse lacked. Leptin is produced in the white adipose tissue and signals to the hypothalamus. When leptin levels drop, the body interprets this as a loss of energy, and hunger increases. Mice lacking this protein eat until they are four times their normal size. Leptin, however, plays a different role in diet-induced obesity in rodents and humans. Because adipocytes produce leptin, leptin levels are elevated in the obese. However, hunger remains, and—when leptin levels drop due to weight loss—hunger increases. The drop of leptin is better viewed as a starvation signal than the rise of leptin as a satiety signal. However, elevated leptin in obesity is known as leptin resistance. The changes that occur in the hypothalamus to result in leptin resistance in obesity are currently the focus of obesity research.
The first reliably documented report of Psilocybe semilanceata intoxication involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's Green Park. According to the chemist Augustus Everard Brande, the father and his four children experienced typical symptoms associated with ingestion, including pupil dilation, spontaneous laughter and delirium. The identification of the species responsible was made possible by James Sowerby's 1803 book Coloured Figures of English Fungi or Mushrooms, which included a description of the fungus, then known as Agaricus glutinosus (originally described by Moses Ashley Curtis in 1780). According to German mycologist Jochen Gartz, the description of the species is "fully compatible with current knowledge about Psilocybe semilanceata." In the early 1960s, the Swiss scientist Albert Hofmann—known for the synthesis of the psychedelic drug LSD—chemically analyzed P. semilanceata fruit bodies collected in Switzerland and France by the botanist Roger Heim. Using the technique of paper chromatography, Hofmann confirmed the presence of 0.25% (by weight) psilocybin in dried samples. Their 1963 publication was the first report of psilocybin in a European mushroom species; previously, it had been known only in Psilocybe species native to Mexico, Asia and North America. This finding was confirmed in the late 1960s with specimens from Scotland and England, Czechoslovakia (1973), Germany (1977), Norway (1978), and Belgium and Finland (1984).
=== Malaria === A number of different proteins on the surface of Plasmodium falciparum malaria parasites help the invaders bind to red blood cells. But once attached to host blood cells, the parasites need to shed the 'sticky' surface proteins that would otherwise interfere with entrance into the cell. The Sheddase enzyme, specifically called PfSUB2 in this example, is required for the parasites to invade cells; without it, the parasites die. The sheddase is stored in and released from cellular compartments near the tip of the parasite, according to the study. Once on the surface, the enzyme attaches to a motor that shuttles it from front to back, liberating the sticky surface proteins. With these proteins removed, the parasite gains entrance into a red blood cell. The entire invasion lasts about 30 seconds and without this ADAM metallopeptidase, malaria would be ineffective at invading the red blood cells.
=== New rankings system === The UFC introduced official rankings in February 2013 using a weekly media voting panel. On June 20, 2026, the promotion began replacing that system with the Meta UFC Rankings, an Elo‑based mathematical model designed to prioritize objectivity through factors such as opponent quality, activity, and decay for long layoffs or outdated wins. The new framework removes pound‑for‑pound rankings and minimizes human involvement, with the media panel continuing only during a transition period.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.